# A Study of CS1002 in Subjects with Advanced Solid Tumors

> **NCT03523819** · PHASE1 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 91 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** CS1002
- **DRUG:** CS1003

## Key facts

- **NCT ID:** NCT03523819
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2022-01-18
- **Final completion:** 2022-01-18
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523819, "A Study of CS1002 in Subjects with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03523819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*